ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ドキソフィリン

Doxofylline

HCID 50942
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
69975-86-6
標準SMILES
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
InChIKey
HWXIGFIVGWUZAO-UHFFFAOYSA-N
分子式
C11H14N4O4
平均分子量
266.25 g/mol
単同位体質量
266.10150494

概要

Doxofylline is an oxopurine that is a derivative of xanthine, methylated at N-1 and N-3 and carrying a 1,3-dioxolan-2-ylmethyl group at N-7, used in the treatment of asthma. It has a role as a bronchodilator agent, an anti-asthmatic drug and an antitussive. It is functionally related to a 7H-xanthine.

名称と識別子

優先名称
Doxofylline
IUPAC
7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
現地名
ドキソフィリン
英語名
Doxofylline
分子式
C11H14N4O4
分子量
266.25

名称と別名

DOXOFYLLINE69975-86-6DoxophyllineDioxyfillineAnsimarVentaxDoxofilinaDoxofyllinumSynasmaABC 12/37-(1,3-Dioxolan-2-ylmethyl)theophyllineDTXSID7022968
名称をさらに表示
ドキソフィリン7-(1,3-ジオキソラン-2-イルメチル)テオフィリン7-[(1,3-ジオキソラン-2-イル)メチル]-3,7-ジヒドロ-1,3-ジメチル-1H-プリン-2,6-ジオン3,7-ジヒドロ-7-(1,3-ジオキソラン-2-イルメチル)-1,3-ジメチル-1H-プリン-2,6-ジオン7-(1,3-ジオキソラン-2-イルメチル)-3,7-ジヒドロ-1,3-ジメチル-1H-プリン-2,6-ジオンジオキシフィリン7-(1,3-ジオキソラン-2-イルメチル)-1,3-ジメチル-1H-プリン-2,6-ジオン7-(1,3-ジオキソラン-2-イルメチル)-1,3-ジメチルキサンチンドキソフィリン‐D67-(1,3-ジオキソラン-2-イルメチル)-1,3-ジメチル-7H-プリン-2,6(1H,3H)-ジオン7-[(1,3-ジオキソラン-2-イル)メチル]-1,3-ジメチル-2,3,6,7-テトラヒドロ-1H-プリン-2,6-ジオンドキソフィリン-d6abc12/3AnsirnarMAXIVENTABC 1213DoxofyliineDoxof3rlline
ABC-12/3MPM23GMO7ZNSC-7596451H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-CHEBI:94714DTXCID002968TMDO7-[(1,3-dioxolan-2-yl)methyl]-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

物性

構造計算による物性補完中

XLogP
-0.9
極性表面積
76.9 Ų
水素結合供与体数
0
水素結合受容体数
5
回転可能結合数
2
重原子数
19
形式電荷
0
複雑度
398

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Brochodilators

Solubility · 2 件

Insoluble

>39.9 [ug/mL] (The mean of the results at pH 7.4)

物理化学的性質

融点
144 · 144-146°C
沸点
409.46 °C · 409.46°C (rough estimate)
比重(密度)
1.2896 · 1.2896 (rough estimate)
屈折率
1.6 · 1.6000 (estimate)
貯蔵温度
2 · under inert gas (nitrogen or Argon) at 2-8°C
溶解性
DMSO(微量)、メタノール(微量)
外見
個体
酸解離定数(Pka)
0.42 · 0.42±0.70(Predicted)
色
ホワイトからオフホワイト
水溶解度
溶ける
Merck
14 · 14,3438
InChI
InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
InChIKey
HWXIGFIVGWUZAO-UHFFFAOYSA-N

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P337+P317, P362+P364, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 4 (100%)

安全データ

毒性
LD50 in mice (mg/kg): 841 orally; 215.6 i.v.; in rats: 1022.4 orally, 445 i.p. (Franzone)
hs_code
29399990
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36/37

化学と産業

薬理情報

ATC Code · 2 件

R - Respiratory system

QR - Respiratory system

Protein BindingAt pH 7.4, the fraction of plasma protein binding is about 48%.
Pharmacodynamics · 1 件

Doxofylline is a methylxanthine bronchodilator with potent bronchodilator activity comparable to that of theophylline. In animal studies, doxofylline demonstrated to attenuate bronchoconstriction, inflammatory actions and the release of thromboxane A2 (TXA2) when challenged with platelet-activating factor. Doxofylline does not demonstrate direct inhibition of any histone deacetylase (HDAC) enzymes or known PDE enzyme isoforms and did not act as an antagonist at A2 or A2 receptors. The affinity for adenosine A1, A2A and A2B receptors are reported to be all higher than 100 µM. It only displays an inhibitory action against PDE2A1 and antagonism at adenosine A(2A) at high concentrations. A study demonstrated that doxofylline interacts with β2-adrenoceptors to induce blood vessel relaxation and airway smooth muscle relaxation. In dog studies, doxofylline decreased airway responsiveness at a dose that did not affect heart rate and respiratory rate.

Mechanism of Action · 1 件

The main mechanism of action of doxofylline is unclear. One of the mechanisms of action of is thought to arise from the inhibition of phosphodiesterase activity thus increasing the levels of cAMP and promoting smooth muscle relaxation. The interaction of doxofylline with beta-2 adrenoceptors was demonstrated by a study using nonlinear chromatography, frontal analysis and molecular docking. Serine 169 and serine 173 residues in the receptor are thought to be critical binding sites for doxofylline where hydrogen bonds are formed. Via mediating the actions of beta-2 adrenoceptors, doxofylline induces blood vessel relaxation and airway smooth muscle relaxation. There is also evidence that doxofylline may exert anti-inflammatory actions by reducing the pleurisy induced by the inflammatory mediator platelet activating factor (PAF) according to a rat study. It is suggested that doxofylline may play an important role in attenuating leukocyte diapedesis, supported by mouse preclinical studies where doxofylline administration was associated with inhibited leukocyte migration across vascular endothelial cells in vivo and in vitro.Unlike theophylline, doxofylline does not inhibit tumor necrosis factor-induced interleukin (IL)-8 secretion in ASM cells.

関連反応

1 件
反応記録を作成
HRID 2243787 の反応式
HRID 2243787生成物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
69975-86-6
PubChem CID
50942
DTXSID
DTXSID7022968
ChEMBL
CHEMBL1527608
ChEBI
CHEBI:94714
UNII
MPM23GMO7Z
EC Number
274-239-6
Nikkaji
J23.295E
SMILES
N1(CC2OCCO2)C2=C(N(C)C(=O)N(C)C2=O)N=C1
CAS データベース
69975 · 69975-86-6(CAS DataBase Reference)
Biological Half-Life · 1 件

Following administration of a single intravenous dose of 100 mg over 10 minutes in adults with chronic bronchitis, the elimination half life of doxofylline was 1.83 ± 0.37 hours. Following oral administration of 400 mg twice daily for 5 days in adults with chronic bronchitis, the mean elimination half life was 7.01 ± 0.80 hours.

Metabolism/Metabolites · 1 件

Doxofylline is thought to undergo hepatic metabolism which accounts for 90% of total drug clearance. β-hydroxymethyltheophylline was detected in the serum and urine after oral administration of 400 mg given in healthy subjects. The circulating metabolite was devoid of any significant pharmacological activity.

MeSH Pharmacological Classification · 3 件

Agents that suppress cough. They act centrally on the medullary cough center. EXPECTORANTS, also used in the treatment of cough, act locally.

Agents that cause an increase in the expansion of a bronchus or bronchial tubes.

Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases.

Absorption, Distribution and Excretion · 4 件

After repeated administrations doxofylline reaches the steady-state in about 4 days. Following oral administration of 400 mg doxofylline twice daily for 5 days in adults with chronic bronchitis, the peak plasma concentrations (Cmax) at steady state ranged from 5.78 to 20.76 mcg/mL. The time to reach maximum concentration (Tmax) was 1.19 ± 0.19 hours. The absolute bioavailability of doxofylline in healthy subjects was 63 ± 25%.

Less than 4% of an orally administered dose is excreted unchanged in the urine due to extensive hepatic metabolism.

Doxofylline demonstrates a short distribution phase following intravenous administration of 100 mg given in adults with chronic bronchitis. As methylxanthines are distributed to all body compartments, doxofylline may be detected in breast milk and placenta.

Following oral administration of 400 mg doxofylline twice daily for 5 days, the total clearance was 555.2 ± 180.6 mL/min.

応用分野 · 1 件

説明Doxofylline, a xanthine bronchodilator related to theophylline, is useful in the treatment of asthma and similar bronchospastic disorders. It has minimal activity on intestinal smooth muscle and the cardiovascular system, and is reportedly devoid of the behavioral effects of theophylline.

上流・下流製品情報

上流原料

トルエン-4-スルホン酸テオフィリン3-クロロ-1,2-プロパンジオール2,4,6-トリス(クロロメチル)-1,3,5-トリオキサン2-クロロメチル-1,3-ジオキソラン2-ブロモメチル-1,3-ジオキソランエチレングリコール水酸化ナトリウムTetrabutylammomium bromideアセトン